Benzinga - by Benzinga Insights, Benzinga Staff Writer.
On March 6, a recent SEC filing unveiled that WARBURG PINCUS CO, Board Member at Sotera Health (NASDAQ:SHC) made an insider sell.
What Happened: CO's recent Form 4 filing with the U.S. Securities and Exchange Commission on Wednesday unveiled the sale of 16,594,363 shares of Sotera Health. The total transaction value is $237,423,848.
The latest update on Thursday morning shows Sotera Health shares up by 0.07%, trading at $14.24.
Get to Know Sotera Health Better Sotera Health Co provides sterilization, analytical lab testing, and advisory services to help ensure that medical, pharmaceutical and food products are safe for healthcare practitioners, patients, and consumers. The company operates in three segments: Sterigenics, Nordion, and Nelson Labs. Sterigenics provides outsourced terminal sterilization and irradiation services for medical device, pharmaceutical, food safety, and advanced applications; Nordion provides Co-60 and gamma irradiators, which are the key components to the gamma sterilization process; and Nelson Labs provides outsourced microbiological and analytical chemistry testing for the medical device and pharmaceutical industries. Its geographical segments are the United States, Canada, Europe, and other regions.
Sotera Health: Financial Performance Dissected Revenue Growth: Sotera Health's revenue growth over a period of 3 months has been noteworthy. As of 31 December, 2023, the company achieved a revenue growth rate of approximately 23.31%. This indicates a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.
Profitability Metrics:
- Gross Margin: Achieving a high gross margin of 58.05%, the company performs well in terms of cost management and profitability within its sector.
- Earnings per Share (EPS): With an EPS below industry norms, Sotera Health exhibits below-average bottom-line performance with a current EPS of 0.14.
Understanding Financial Valuation:
- Price to Earnings (P/E) Ratio: A higher-than-average P/E ratio of 79.06 suggests caution, as the stock may be overvalued in the eyes of investors.
- Price to Sales (P/S) Ratio: The current P/S ratio of 3.84 is below industry norms, suggesting potential undervaluation and presenting an investment opportunity for those considering sales performance.
- EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation & Amortization): With a lower-than-industry-average EV/EBITDA ratio of 14.88, Sotera Health presents a potential value opportunity, as investors are paying less for each unit of EBITDA.
Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.
Why Insider Transactions Are Key in Investment Decisions While insider transactions provide valuable information, they should be part of a broader analysis in making investment decisions.
Exploring the legal landscape, an "insider" is defined as any officer, director, or beneficial owner holding more than ten percent of a company's equity securities, as stipulated by Section 12 of the Securities Exchange Act of 1934. This encompasses executives in the c-suite and major hedge funds. These insiders are required to report their transactions through a Form 4 filing, which must be submitted within two business days of the transaction.
Highlighted by a company insider's new purchase, there's a positive anticipation for the stock to rise.
But, insider sells may not necessarily indicate a bearish view and can be motivated by various factors.
Essential Transaction Codes Unveiled When analyzing transactions, investors tend to focus on those in the open market, detailed in Table I of the Form 4 filing. A P in Box 3 denotes a purchase,while S signifies a sale. Transaction code C signals the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
Check Out The Full List Of Sotera Health's Insider Trades.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.